icd9_map_quan_deyo: Quan adaptation of Deyo/Charlson comorbidities

In icd: Comorbidity Calculations and Tools for ICD-9 and ICD-10 Codes

Description

Derived automatically from the SAS code used in the original publication. According to the referenced study, this provides the best predictor of in-patient to <30d mortality. Of note, Deyo drops the distinction between leukemia, lymphoma and non-metastatic cancer. As far as I have looked into this, in the rare cases where someone had two or three of leukemia, lymphoma and non-metastatic cancer, the Quan adaptation would give a lower Charlson score than the original scheme. The original Deyo Charlson to ICD-9-CM groups does include distinct categories for these things.

Format

list of character vectors, each named by co-morbidity

References

Quan, Hude, Vijaya Sundararajan, Patricia Halfon, Andrew Fong, Bernard Burnand, Jean-Christophe Luthi, L. Duncan Saunders, Cynthia A. Beck, Thomas E. Feasby, and William A. Ghali. "Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data." Medical Care 43, no. 11 (November 1, 2005): 1130-39. http://www.ncbi.nlm.nih.gov/pubmed/16224307 http://web.archive.org/web/20110225042437/http://www.chaps.ucalgary.ca/sas

See Also

comorbid_quan_deyo icd9_comorbid_quan_deyo icd10_comorbid_quan_deyo

Other comorbidity maps: icd10_map_ahrq_pcs, icd9_map_ahrq, icd9_map_elix, icd9_map_hcc, icd9_map_pccc, icd9_map_quan_elix, icd9_map_single_ccs

Other comorbidities: comorbid_hcc(), comorbid(), icd10_map_ahrq_pcs, icd9_map_ahrq, icd9_map_elix, icd9_map_hcc, icd9_map_pccc, icd9_map_quan_elix, icd9_map_single_ccs

icd documentation built on July 2, 2020, 4:07 a.m.